Results 51 to 60 of about 259,945 (244)

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective

Frontiers in Immunology, 2020
Targeting PD-L1 and PD-1 interactions is a relatively new therapeutic strategy used to treat cancer. Inhibitors of PD-1/PD-L1 include peptides, small molecule chemical compounds, and antibodies.
Libin Guo, Ran Wei, Yao Lin, Hang Fai Kwok   +3 more
doaj   +1 more source

Elevated numbers of PD-L1 expressing B cells are associated with the development of AIDS-NHL. [PDF]

, 2019
The risk for non-Hodgkin lymphoma (NHL) is markedly increased in persons living with human immunodeficiency virus (HIV) infection, and remains elevated in those on anti-retroviral therapy (cART).
Conti, David V, Cozen, Wendy, Epeldegui, Marta, Guo, Yu, Martínez-Maza, Otoniel, Penichet, Manuel L   +5 more
core  

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Cuproptosis and Disulfidptosis Converge to Empower PD‐L1 Checkpoint Therapy via Cadict‐Induced PD‐L1 Translation

Advanced Science
Immune checkpoint blockade (ICB) has emerged as a cornerstone of cancer therapy, yet its effectiveness remains restricted in PD‐L1‐low malignancies due to insufficient target expression.
Shaoqing Huang, Shiyao Song, Xinhua Zhang, Jialing Gao, Ruihan Pu, Jiatong Dai, Xiaoxue Wu, Lulu Chen, Qinghai Li, Xiaoting Liu, Qi Zhou, Mei Song, Weiling He   +12 more
doaj   +1 more source

PD-L1 blockade enhances anti-tumor efficacy of NK cells

OncoImmunology, 2018
Anti-PD-1/anti-PD-L1 therapies have shown success in cancer treatment but responses are limited to ~ 15% of patients with lymphocyte infiltrated, PD-L1 positive tumors.
Jeremiah L. Oyer, Sarah B. Gitto, Deborah A. Altomare, Alicja J. Copik   +3 more
doaj   +1 more source

Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer

Scientific Reports, 2021
PD-L1 expression is the most useful predictive biomarker for immunotherapy efficacy on non-small cell lung cancer (NSCLC), and CD8+ tumor-infiltrating lymphocytes (CD8+ TILs) play an essential role in the clinical activity of immunotherapy.
Yoshihisa Shimada, Jun Matsubayashi, Yujin Kudo, Sachio Maehara, Susumu Takeuchi, Masaru Hagiwara, Masatoshi Kakihana, Tatsuo Ohira, Toshitaka Nagao, Norihiko Ikeda   +9 more
doaj   +1 more source

Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory. [PDF]

, 2019
PD-L1 on the surface of tumor cells binds its receptor PD-1 on effector T cells, thereby suppressing their activity. Antibody blockade of PD-L1 can activate an anti-tumor immune response leading to durable remissions in a subset of cancer patients ...
Belair, Cassandra D, Blelloch, Robert, Chang, Anthony, Chu, Brandon, Fong, Lawrence, Fu, Qi, Hu, Tianyi, Lang, Ursula E, Montabana, Elizabeth, Pai, Chien-Chun, Poggio, Mauro   +10 more
core  

Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis that may be harmed by adjuvant chemotherapy [PDF]

, 2016
A recent phase II study of patients with metastatic colorectal carcinoma showed that mismatch repair gene status was predictive of clinical response to PD-1–targeting immune checkpoint blockade.
Allen, Wendy L., Coleman, Helen G., Dunne, Philip D., Johnston, Patrick G., Lawler, Mark, Longley, Daniel B., Loughrey, Maurice, McArt, Darragh G., McDade, Simon, O'Reilly, Paul G., Salto-Tellez, Manuel, Van Schaeybroeck, Sandra   +11 more
core   +1 more source

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1−PD-L1+ Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer

Cell Death and Disease, 2021
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous group of myeloid cells that are closely related to tumor immune escape, but the mechanism by which MDSCs regulate B cells has not been elucidated.
Min Liu, Feng Wei, Jian Wang, Wenwen Yu, Meng Shen, Ting Liu, Dong Zhang, Yang Wang, Xiubao Ren, Qian Sun   +9 more
doaj   +1 more source